AKT1 and cancer: TMT targets key metabolic pathways implicated in tumor growth and survival such as glycolysis, glutaminolysis, IGF-1/PI3K-AKT-mTOR, angiogenesis, apoptosis resistance, and Wnt/β-catenin signaling, while also disrupting microenvironmental drivers including cancer stemness, metastasis, acidosis, hypoxia, and chronic inflammation.